Sage Therapeutics to Present Brexanolone Postpartum Depression Data and SAGE-217 Major Depressive Disorder Data at Upcoming Spring Medical Meetings
Sage Therapeutics, Inc. (SAGE)
Last sage therapeutics, inc. earnings: 2/27 06:30 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.sagerx.com/investor-relations
Company Research
Source: Business Wire
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sage Therapeutics (NASDAQ: SAGE) a clinical-stage biopharmaceutical company developing novel medicines to treat life-altering central nervous system (CNS) disorders, today announced that data from clinical studies of its proprietary i.v. formulation of brexanolone for the treatment of postpartum depression (PPD) as well as SAGE-217, its novel, next-generation positive allosteric modulator of synaptic and extrasynaptic GABAA receptors, in major depressive disorder (MDD), will be presented in podium and poster sessions at the following upcoming medical meetings: North American Society for Psychosocial Obstetrics and Gynecology (NASPOG)2018 Biennial Meeting, April 20-22, 2018 in Philadelphia Date and Time: April 20, 2018, 12:15 p.m. – 1:15 p.m. ET Location: University of Pennsylvania Biomedical Research Building Titl
Show less
Read more
Impact Snapshot
Event Time:
SAGE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAGE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAGE alerts
High impacting Sage Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
SAGE
News
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors Sage Therapeutics, Inc. - SAGEGlobeNewswire
- Registration for Association of Bioscience Financial Officers 2024 National Conference in May in Boston Nearing Full Capacity [Yahoo! Finance]Yahoo! Finance
- Ex-Stanford President's AI Drug Startup Pulls In $1 Billion in Commitments [BNN Bloomberg (Canada)]BNN Bloomberg
- Sage Therapeutics, Inc. (NASDAQ: SAGE) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.MarketBeat
- Sage (SAGE) Down 20% on Parkinson's Study Missing Primary Goal [Yahoo! Finance]Yahoo! Finance
SAGE
Earnings
- 2/14/24 - Beat
SAGE
Sec Filings
- 4/24/24 - Form ARS
- 4/24/24 - Form DEFA14A
- 4/24/24 - Form DEF
- SAGE's page on the SEC website